Are Patients With Chronic Inflammatory Disease at Risk for Early Menopause?

Article

Lead researcher Dr Janet McLaren discusses the results of a new study exploring new concerns that rheumatoid arthritis, lupus, and inflammatory bowel disease may lead to premature ovarian failure and early menopause.

Chronic inflammatory diseases such as rheumatoid arthritis, lupus, and inflammatory bowel disease, negatively affect patients’ physical and psychological health. In fact, these diseases have been associated with gynecological complications, including menstrual and pelvic abnormalities, which can further negatively impact quality of life. Now, there are new concerns that these diseases may lead to premature ovarian failure and early menopause.

We invited lead researcher Dr Janet McLaren to discuss the results of this new study, which was presented at the 67th Annual Meeting of the American Society for Reproductive Medicine. Dr McLaren is an assistant professor in the division of reproductive endocrinology and infertility at the University of Alabama at Birmingham. 

Are Patients With Chronic Inflammatory Disease at Risk for Early Menopause?

Reference:
McLaren JF, Haynes K, Barnhart KT, et al. Early menopause in women with chronic inflammatory disease: a population-based cohort study. Presented at the 67th Annual Meeting of the American Society for Reproductive Medicine. Oct. 17, 2011; Orlando.

Recent Videos
Rossella Nappi, MD, discusses benefits of fezolinetant against vasomotor symptoms | Image Credit: imsociety.org
JoAnn Pinkerton discusses elinzanetant's crucial role in VMS therapy | Image Credit: uvahealth.com
Supporting women through menopause with knowledge and care | Image Credit: © SHOTPRIME STUDIO - © SHOTPRIME STUDIO - stock.adobe.com.
How fezolinetant revolutionizes non-hormonal menopause therapy | Image Credit: imsociety.org
Gulf War exposures linked to early menopause in women veterans | Image Credit: linkedin.com.
Vanessa Muñiz discusses benefits of clinical hypnosis against hot flashes | Image Credit: mindbodymedicine.artsandsciences.baylor.edu
Elinzanetant displays positive phase 3 safety and efficacy data against VMS | Image Credit: © toeytoey - © toeytoey - stock.adobe.com.
Related Content
© 2024 MJH Life Sciences

All rights reserved.